18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients-Reference-Cited by-同舟云学术

18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients

Published:2022-04-22 Issue:7 Volume:47 Page:583-589
ISSN:1536-0229
Container-title:Clinical Nuclear Medicine
language:en
Short-container-title:Clin Nucl Med

Author:

van der Hiel Bernies,Blankenstein Stephanie A.,Aalbersberg Else A.,Wondergem Maurits,Stokkel Marcel P.M.,van de Wiel Bart A.,Klop W. Martin C.,van Akkooi Alexander C.J.,Haanen John B.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Reference20 articles.

1. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;N Engl J Med,2011

2. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial;Lancet,2012

3. Improved overall survival in melanoma with combined dabrafenib and trametinib;N Engl J Med,2015

4. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma;N Engl J Med,2014

5. Perioperative BRAF inhibitors in locally advanced stage III melanoma;J Surg Oncol,2017

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reconsidering S100B: Why it is time to abandon its use in detecting disease recurrence in stage III melanoma patients;European Journal of Surgical Oncology;2024-07

2. 18F-FDG PET/CT metabolism multi-parameter prediction of chemotherapy efficacy in locally progressive gastric cancer;Annals of Nuclear Medicine;2024-03-27

3. 18F-FDG PET/CT metabolism multi-parameter prediction of chemotherapy efficacy in locally progressive gastric cancer;2023-12-12

4. PET-CT underestimates the true pathological extent of disease at lymphadenectomy for melanoma patients after systemic therapy;European Journal of Surgical Oncology;2023-10

5. The role of imaging and sentinel lymph node biopsy in patients with T3b-T4b melanoma with clinically negative disease;Frontiers in Oncology;2023-05-08